| [1] |
Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood, 2001, 98(9)：2730-2735.
|
| [2] |
George JN. How I treat patients with thrombotic thrombocytopenic purpura. Blood, 2010, 116(20)：4060-4069.
|
| [3] |
Rozdzinski E, Hertenstein B, Schmeiser T, et al. Thrombotic thrombocytopenic purpura in early pregnancy with maternal and fetal survival. Ann Hematol, 1992, 64(5)：245-248.
|
| [4] |
阮长耿，余自强. 2012版血栓性血小板减少性紫癜诊断与治疗中国专家共识解读. 临床血液学杂志，2013, 26(2)：145-146.
|
| [5] |
Sadler JE. Von Willebrand factor, ADAMTS13 and thrombotic thrombocytopenic purpura. Blood, 2008, 112(1)：11-18.
|
| [6] |
Sanchez-Luceros A, Farias CE, Amaral MM, et al. Von Willebrand factorcleaving protease (ADAMTS13) activity in normal non-pregnant women，pregnant and post-delivery women. Thromb Haemost, 2004, 92(6)：1320-1326.
|
| [7] |
Hori Y, Hayakawa M, Isonishi A，et al. ADAMTS13 unbound to larger von Willebrand factor multimers in cryosupernatant：implications for selection of plasma preparations for thrombotic thrombocytopenic purpura treatment. Transfusion, 2013, 53(12): 3192-3202.
|
| [8] |
Kondo H, Imamura Z. Effects of intravenous immunoglobulin in a patient with intermittent thrombotic thrombocytopenic purpura. Br J Haematol, 2000, 108(3)：880-882.
|
| [9] |
Guzman Moreno R. B-cell depletion in autoimmune diseases. Advances in autoimmunity. Autoimmun Rev, 2009, 8(7)：585-590.
|
| [10] |
Chemnitz JM, Uener J, Hallek M, et al. Long-term follow up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab. Ann Hematol, 2010, 89(10)：1029-1033.
|
| [11] |
Mao SP, Chang CC, Chen SY，et al. Gestational thrombocytopenia complicated with macrosomia, failure to progress in active labor, and postpartum hemorrhage. Taiwan J Obstet Gynecol, 2007, 46(2)：177-179.
|